Stock comparison
Genmab A/S
Gyre Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
GYRE
Gyre Therapeutics
Market cap
$587.78M
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | GYRE | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 44D | GMAB |
| Benjamin Graham | 64C | 57D | GMAB |
| Philip Fisher | 48D | 60C | GYRE |
| Peter Lynch | 25F | 47D | GYRE |
| Joel Greenblatt | 76B | 44D | GMAB |
| Charlie Munger | 68C | 49D | GMAB |
| Terry Smith | 71C | 50C | GMAB |
Side-by-side metrics
| Metric | GMAB | GYRE |
|---|---|---|
| Market cap | $16.5B | $587.78M |
| P/E (TTM) | 6.2x | - |
| EV/EBIT | 12.0x | 49.6x |
| ROIC (TTM) | 43.78% | 0.43% |
| Gross margin | 93.88% | 95.09% |
| Net margin | 18.23% | -5.37% |
| Revenue CAGR 5y | -18.45% | 99.65% |
| EPS CAGR 5y | -23.48% | - |
| Debt / Equity | 0.1x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- Net margin18.23%vs -5.37%+129%
- ROIC (TTM)43.78%vs 0.43%+99%
- Market cap$16.5Bvs $587.78M+96%
- EV/EBIT12.0xvs 49.6x+76%
GYRE leads on
- Revenue CAGR 5y99.65%vs -18.45%+119%
- P/E (TTM)-vs 6.2x+107%
- Debt / Equity0.0xvs 0.1x+89%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.